14.70p-0.10 (-0.68%)24 Dec 2024, 08:00
Jump to:
Oncimmune Holdings PLC Fundamentals
Company Name | Oncimmune Holdings PLC | Last Updated | 2024-12-24 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 111.773 m | Market Cap | £16.43 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | £0.06 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0.8848 | Debt Equity Ratio | 0 |
Asset Equity Ratio | -4.6570 | Cash Equity Ratio | -0.7134 |
Quick Ratio | 1.0088 | Current Ratio | 1.14 |
Price To Book Value | 0 | ROCE | 0 |
Oncimmune Holdings PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Oncimmune Holdings PLC Company Financials
Assets | 2023 | 2022 | 2021 |
---|---|---|---|
Tangible Assets | £591,000.00 | £1.34 m | £1.59 m |
Intangible Assets | £2.06 m | £4.59 m | £5.69 m |
Investments | 0 | 0 | 0 |
Total Fixed Assets | £2.87 m | £6.55 m | £8.22 m |
Stocks | £235,000.00 | £430,000.00 | £143,000.00 |
Debtors | £1.92 m | £1.36 m | £1.64 m |
Cash & Equivalents | £3.21 m | £1.43 m | £8.63 m |
Other Assets | 0 | 0 | 0 |
Total Assets | £8.44 m | £10.16 m | £19.36 m |
Liabilities | 2023 | 2022 | 2021 |
---|---|---|---|
Creditors within 1 year | £1.42 m | £7.82 m | £4.85 m |
Creditors after 1 year | £6.36 m | £6.52 m | £9.28 m |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £7.78 m | £14.34 m | £14.13 m |
Net assets | £657,000.00 | -£4.18 m | £5.23 m |
Equity | 2023 | 2022 | 2021 |
---|---|---|---|
Called up share capital | £741,000.00 | £695,000.00 | £691,000.00 |
Share Premium | £42.68 m | £40.63 m | £40.50 m |
Profit / Loss | -£5.93 m | -£6.58 m | -£6.06 m |
Other Equity | £657,000.00 | -£4.18 m | £5.23 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £657,000.00 | -£4.18 m | £5.23 m |
Ratios | 2023 | 2022 | 2021 |
---|---|---|---|
Debt Ratio | £0.88 | £0.57 | 0 |
Debt-to-Equity | £7.56 | £1.32 | 0 |
Assets / Equity | -4.6570 | -4.6570 | -4.6570 |
Cash / Equity | -0.7134 | -0.7134 | -0.7134 |
EPS | -£0.08 | -£0.10 | -£0.08 |
Cash Flow | 2023 | 2022 | 2021 |
---|---|---|---|
Cash from operating activities | -£6.79 m | -£6.87 m | -£4.53 m |
Cashflow before financing | -£9.81 m | -£6.22 m | £5.25 m |
Increase in Cash | £1.78 m | -£7.15 m | £4.40 m |
Income | 2023 | 2022 | 2021 |
---|---|---|---|
Turnover | £1.15 m | £2.32 m | £3.72 m |
Cost of sales | £360,000.00 | £1.12 m | £865,000.00 |
Gross Profit | £792,000.00 | £1.20 m | £2.86 m |
Operating Profit | -£3.92 m | -£6.29 m | -£5.14 m |
Pre-Tax profit | -£5.93 m | -£6.58 m | -£6.06 m |
Oncimmune Holdings PLC Company Background
Sector | Healthcare |
---|---|
Activities | Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS. |
Latest Interim Date | 21 May 2024 |
Latest Fiscal Year End Date | 29 Feb 2024 |
Oncimmune Holdings PLC Directors
Appointed | Name | Position |
---|---|---|
2016-11-07 | Mr. Andrew Vaughan Unitt | Non-Executive Director |
2020-05-04 | Mr. Richard Simon Sharp | Non-Executive Director |
2024-11-11 | Mr. Alistair Macdonald | Non-Executive Director,Chairman |
2022-07-08 | Mr. Meinhard Folkert Schmidt | Non-Executive Director,Chairman |
2020-06-04 | Mr. Geoffrey Neil Hamilton-Fairley | Non-Executive Director,Vice Chairman |
2016-06-06 | Mr. Robert Hoyles Page | Executive Director,Chief Financial Officer |
2023-10-12 | Mr. Timothy Brian Bunting | Non-Executive Director,Deputy Chairman |
2019-11-05 | Mr. Andrew Millet | Executive Director,Chief Financial Officer and Company Secretary |
2020-06-04 | Mr. Carsten Schroeder | Non-Executive Director |
2023-07-12 | Dr. Adam Mark Hill | Executive Director,Chief Executive Officer |
2021-01-19 | Dr. To Cheung | Non-Executive Director |
2022-11-04 | Mr. Matthew Hall | Executive Director,Chief Financial Officer |
2024-11-11 | Mr. John Howard Goold | Non-Executive Director |
2024-11-11 | Mr. Martin John Gouldstone | Executive Director,Chief Executive Officer |
Oncimmune Holdings PLC Contact Details
Company Name | Oncimmune Holdings PLC |
---|---|
Address | Hucknall Road, Clinical Sciences Building, City Hospital, Nottingham, NG5 1PB |
Telephone | |
Website | https://www.oncimmune.com |
Oncimmune Holdings PLC Advisors
Nominated Adviser | Zeus Capital Ltd |
---|---|
Phone | +44 2038295000 |
Auditor | Grant Thornton (UK) LLP |
---|---|
Phone | +44 1908660666 |
Fax | +44 1908690180 |
Stockbroker | Zeus Capital Ltd |
---|---|
Phone | +44 2038295000 |
Registrar | Capita Asset Services |
---|---|
Phone | +44 8716640300 |
Fax | +44 2086392342 |
Financial PR Adviser | Consilium Strategic Communications |
---|---|
Phone | +44 2037095700 |
Solicitor | Peachey & Co LLP |
---|---|
Phone | (020) 7316 5200 |
Fax | (020) 7316 5222 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
North Atlantic Smaller Companies Investment Trust PLC | 3,770.00 | 4.72 |
Harworth Group PLC | 176.50 | 4.44 |
Mobico Group PLC | 79.85 | 4.17 |
Ithaca Energy PLC | 107.00 | 3.88 |
Airtel Africa PLC | 112.80 | 3.87 |
Bakkavor Group PLC | 149.50 | 3.82 |
Fallers
Company | Price | % Chg |
---|---|---|
Vistry Group PLC | 547.50 | -16.28 |
Persimmon PLC | 1,182.00 | -2.39 |
Entain PLC | 681.40 | -1.25 |
Firstgroup PLC | 164.40 | -1.20 |
Jpmorgan Japanese Investment Trust PLC | 555.00 | -1.07 |
Puretech Health PLC | 154.80 | -1.02 |
Risers/fallers data from previous trading day.